Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Antibody–drug conjugates (ADCs) take the advantage of monoclonal antibodies to selectively deliver highly potent cytotoxic drugs to tumor cells, which have become a powerful measure for cancer treatment in recent years. To develop a more effective therapy for human epidermal growth factor receptor 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hang, Wang, Yuxi, Wu, Yangping, Jiang, Xiaohua, Tao, Yiran, Yao, Yuqin, Peng, Yujia, Chen, Xiangzheng, Fu, Yuyin, Yu, Lin, Wang, Ruixue, Lai, Qinhuai, Lai, Weirong, Li, Wenting, Kang, Yuhuan, Yi, Shuli, Lu, Ying, Gou, Lantu, Wu, Min, Yang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661626/
https://www.ncbi.nlm.nih.gov/pubmed/29263918
http://dx.doi.org/10.1038/sigtrans.2017.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661626/
https://www.ncbi.nlm.nih.gov/pubmed/29263918
http://dx.doi.org/10.1038/sigtrans.2017.15

Ejemplares similares